Effects of josamycin on polymorphonuclear leucocyte chemotaxis

Area of Science:

• Immunology
• Pharmacology
• Microbiology

Background:

• Polymorphonuclear leucocytes (PMNs) are crucial for innate immunity.
• Chemotaxis is a vital function of PMNs in host defense.
• Josamycin is a macrolide antibiotic used to treat bacterial infections.

Purpose of the Study:

• To investigate the impact of josamycin on the chemotactic response of PMNs.
• To determine if josamycin affects PMN function in vivo and in vitro.

Main Methods:

• Oral administration of josamycin to humans (2 g/day) and rats (50 mg/kg/day) for five days.
• In vitro incubation of PMNs with varying concentrations of josamycin (10 mg/l and 25 mg/l).
• Assessment of PMN chemotaxis using standard laboratory assays.

Main Results:

• Oral josamycin administration resulted in a 20% reduction in PMN chemotaxis in both humans and rats.
• In vitro, 10 mg/l josamycin did not alter PMN chemotaxis.
• A 15% decrease in PMN chemotaxis was observed with 25 mg/l josamycin in vitro.

Conclusions:

• Josamycin exhibits a modest inhibitory effect on PMN chemotaxis in vivo and at higher concentrations in vitro.
• The observed reduction in chemotaxis is unlikely to significantly impair immune function in patients treated with josamycin.
• Further research may explore the clinical relevance of these findings in specific patient populations.